Plain-English translation of NCT05625594 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a treatment called CD19-CAR T cells for people with lymphoma in the brain or spinal cord. These are immune cells taken from your own body, specially trained in a laboratory to recognize and attack cancer cells, and then delivered directly into the fluid surrounding your brain. The study will evaluate whether this approach is safe and whether it can help shrink the cancer.
Lymphoma in the brain is difficult to treat because many standard cancer drugs cannot reach the brain effectively. This trial exists to see whether delivering these specially engineered immune cells directly into the brain—rather than through the bloodstream—might be a more effective way to fight this type of cancer.
You likely qualify if…
You likely don't qualify if…
You will have your immune cells collected through a special blood procedure called leukapheresis. You may receive chemotherapy ( and ) to prepare your body, then receive the modified immune cells injected directly into your brain through a small catheter. Throughout the trial, you will have regular brain imaging (MRI and PET scans), blood tests, spinal fluid sampling, and visits to monitor how you respond and watch for side effects. The study involves about 20 participants total and will track your progress over several months to see whether the treatment works and is safe.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States